Skip CCR Main Navigation National Cancer Institute National Cancer Institute U.S. National Institutes of Health www.cancer.gov
CCR - For Our Staff| Home |

Our Science – Doroshow Website

James H. Doroshow, M.D.

Selected Publications

1)  Esworthy RS, Kim BW, Chow J, Shen B, Doroshow JH, Chu FF.
Nox1 causes ileocolitis in mice deficient in glutathione peroxidase-1 and -2.
Free Radic. Biol. Med. 68: 315-25, 2014.
[Journal]
2)  Jeong W, Rapisarda A, Park SR, Kinders RJ, Chen A, Melillo G, Turkbey B, Steinberg SM, Choyke P, Doroshow JH, Kummar S.
Pilot trial of EZN-2968, an antisense oligonucleotide inhibitor of hypoxia-inducible factor-1 alpha (HIF-1a), in patients with refractory solid tumors.
Cancer Chemother. Pharmacol. 73: 343-8, 2014.
[Journal]
3)  Murai J, Zhang Y, Morris J, Ji J, Takeda S, Doroshow JH, Pommier YG.
Rationale for PARP inhibitors in combination therapy with camptothecins or temozolomide based on PARP trapping versus catalytic inhibition.
J. Pharmacol. Exp. Ther. [Epub ahead of print], 2014.
[Journal]
4)  Murai J, Huang SY, Renaud A, Zhang Y, Ji J, Takeda S, Morris J, Teicher B, Doroshow JH, Pommier Y.
Stereospecific PARP trapping by BMN 673 and comparison with olaparib and rucaparib.
Mol. Cancer Ther. 13: 433-43, 2014.
[Journal]
5)  Jeong W, Park SR, Rapisarda A, Fer N, Kinders RJ, Chen A, Melillo G, Turkbey B, Steinberg SM, Choyke P, Doroshow JH, Kummar S.
Weekly EZN-2208 (PEGylated SN-38) in combination with bevacizumab in patients with refractory solid tumors.
Invest New Drugs. 32: 340-6, 2014.
[Journal]
6)  Abrams J, Mooney M, Zweibel J, Christian M, Doroshow J.
Structures Supporting Cancer Clinical Trials. In: Abeloff's Clinical Oncology. Volume 1.
Philadelphia: Elsevier; 2013. In Press. [Book Chapter]
7)  Kummar S, Murgo A, Tomaszewski J, Doroshow J.
Therapeutic Targeting of Cancer Cells: Era of Molecularly Targeted Agents. In: Abeloff's Clinical Oncology. Volume 1.
Philadelphia: Elsevier; 2013. In Press. [Book Chapter]
8)  Weil M, Kummar S, Doroshow J, Chen A.
Yang S, eds.
BRCA Mtations and PARP Inhibitors. In: Handbook of Therapeutic Biomarkers in Cancer.
Singapore: Pan Sanford Publishing Co.; 2013. p. 417-448 [Book Chapter]
9)  Park SR, Speranza G, Piekarz R, Wright JJ, Kinders RJ, Wang L, Pfister T, Trepel JB, Lee MJ, Alarcon S, Steinberg SM, Collins J, Doroshow JH, Kummar S.
A multi-histology trial of fostamatinib in patients with advanced colorectal, non-small cell lung, head and neck, thyroid, and renal cell carcinomas, and pheochromocytomas.
Cancer Chemother. Pharmacol. 71: 981-90, 2013.
[Journal]
10)  Wu Y, Lu J, Antony S, Juhasz A, Liu H, Jiang G, Meitzler JL, Hollingshead M, Haines DC, Butcher D, Roy K, Doroshow JH.
Activation of TLR4 is required for the synergistic induction of dual oxidase 2 and dual oxidase A2 by IFN-gamma and lipopolysaccharide in human pancreatic cancer cell lines.
J. Immunol. 190: 1859-72, 2013.
[Journal]
Click Here to View Expanded Bibliography.

This page was last updated on 4/28/2014.